Objective: The aim of this study was to approach the relationship between the expression of human kallikrein 6 (hK6) in ovarian neoplasm and the clinicopathologic variables and prognosis for finding a new tumor marker...Objective: The aim of this study was to approach the relationship between the expression of human kallikrein 6 (hK6) in ovarian neoplasm and the clinicopathologic variables and prognosis for finding a new tumor marker for ovarian cancer. Methods: Through immunohistochemistry to examine the expression of hK6 in 19 cases with benign, 11 cases with borderline and 45 cases with malignant ovarian neoplasms and statistically analyzed whether the expression of hK6 correlated with the clinicopathologic variables and prognosis in patients with ovarian cancer. Results: The positive rate of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in low-grade ovarian cancer tissues was higher than that in high-grade (68.4% vs 14.3%; P < 0.05); hK6 in late–stage (stage III) was more frequently expressed than that in early-stage (stage I or II) (76.7% vs 26.7%; P < 0.01); and it significantly higher in ovarian carcinomas with lymph node metastases than those without lymph node metastases (77.8% vs 33.3%; P < 0.01 ); moreover, the expression of hK6 in the cancer tissues that the patients died or their pathogenetic condition recurred or their tumor metastasized within 3 years after surgery was higher (75.0%) than that in the cancer tissues that the pathogenetic condition of the patients was stable (42.9%; P < 0.05). Conclusion: The expression of hK6 in ovarian cancer tissues was higher than that in the benign and borderline ovarian neoplasm tissues, and high hK6 expression correlated with late–stage, low-grade, node metastasis and poor prognosis of patients. hK6 could potentially be a novel tumor marker for ovarian cancer that can predict the prognosis of the patients.展开更多
目的通过对阿尔茨海默病(Alzheimer’s disease,AD)和血管性痴呆(vascular dementia,VD)患者血液中高分子量激肽原重链蛋白(heavy chain of high molecular-weight kininogen,hc-HK)和激肽释放酶-6(kallikrein-6,KLK-6)的比较分析,从神...目的通过对阿尔茨海默病(Alzheimer’s disease,AD)和血管性痴呆(vascular dementia,VD)患者血液中高分子量激肽原重链蛋白(heavy chain of high molecular-weight kininogen,hc-HK)和激肽释放酶-6(kallikrein-6,KLK-6)的比较分析,从神经性炎症反应信号通路角度探索AD的发病机制。方法收集AD组、VD组和对照组各15例的外周血标本,分别用蛋白质免疫印迹法检测其中hc-HK蛋白含量,用酶联免疫吸附法检测其中Aβ42和KLK-6蛋白的含量;并对Aβ42与KLK-6进行相关性分析。结果 AD患者外周血中hc-HK含量较VD组或对照组均显著增加(均P<0.01)。AD组患者血液中的KLK-6水平为(4.80±0.78)ng/mL,VD组KLK-6为(3.72±0.87)ng/mL,AD组较VD组明显增加(t=3.57,P<0.01)。AD组患者血浆中Aβ42蛋白浓度为(0.261±0.024)μg/L,与VD组或对照组比较均明显增加(均P<0.01)。通过相关分析发现,在AD组患者血液中KLK-6与Aβ42的增加呈正相关(r=0.65,P<0.01)。结论AD患者外周血液中hc-HK和KLK-6蛋白比VD患者及非痴呆对照有明显增加,提示AD发病中有血凝接触系统的激活;激肽释放酶-激肽系统的异常激活有可能参与了AD的发病过程。展开更多
文摘目的:原核表达人组织激肽释放酶6(human kallikrein 6,hK6),采用杂交瘤技术制备其单克隆抗体,建立免疫组织化学方法,检测hK6在胃癌、乳腺癌组织中的表达情况。方法:通过原核表达hK6融合蛋白免疫BALB/c小鼠,采用杂交瘤技术制备特异性单克隆抗体,并用间接ELISA、SDS-PAGE及Western-blot鉴定抗体,protein A agarose亲和层析柱纯化抗体,并以此抗体建立免疫组织化学方法检测人胃癌、乳腺癌组织中hK6表达情况。结果:成功筛选出4株高分泌型特异性杂交瘤细胞株,其制备抗体可与hK6融合蛋白发生特异性结合;免疫组织学显示,hK6主要分布在胃癌细胞胞浆中,成阳性表达,而在癌旁胃黏膜中成阴性表达;在乳腺癌组织中定位于胞浆,成弱阳性表达,癌旁组织成阴性表达。结论:成功制备了高纯度、特异性的抗hK6单克隆抗体;该抗体为深入研究hK6功能和建立高特异性、高敏感性检测组织和体液中hK6的方法奠定基础。
文摘Objective: The aim of this study was to approach the relationship between the expression of human kallikrein 6 (hK6) in ovarian neoplasm and the clinicopathologic variables and prognosis for finding a new tumor marker for ovarian cancer. Methods: Through immunohistochemistry to examine the expression of hK6 in 19 cases with benign, 11 cases with borderline and 45 cases with malignant ovarian neoplasms and statistically analyzed whether the expression of hK6 correlated with the clinicopathologic variables and prognosis in patients with ovarian cancer. Results: The positive rate of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in low-grade ovarian cancer tissues was higher than that in high-grade (68.4% vs 14.3%; P < 0.05); hK6 in late–stage (stage III) was more frequently expressed than that in early-stage (stage I or II) (76.7% vs 26.7%; P < 0.01); and it significantly higher in ovarian carcinomas with lymph node metastases than those without lymph node metastases (77.8% vs 33.3%; P < 0.01 ); moreover, the expression of hK6 in the cancer tissues that the patients died or their pathogenetic condition recurred or their tumor metastasized within 3 years after surgery was higher (75.0%) than that in the cancer tissues that the pathogenetic condition of the patients was stable (42.9%; P < 0.05). Conclusion: The expression of hK6 in ovarian cancer tissues was higher than that in the benign and borderline ovarian neoplasm tissues, and high hK6 expression correlated with late–stage, low-grade, node metastasis and poor prognosis of patients. hK6 could potentially be a novel tumor marker for ovarian cancer that can predict the prognosis of the patients.
文摘目的通过对阿尔茨海默病(Alzheimer’s disease,AD)和血管性痴呆(vascular dementia,VD)患者血液中高分子量激肽原重链蛋白(heavy chain of high molecular-weight kininogen,hc-HK)和激肽释放酶-6(kallikrein-6,KLK-6)的比较分析,从神经性炎症反应信号通路角度探索AD的发病机制。方法收集AD组、VD组和对照组各15例的外周血标本,分别用蛋白质免疫印迹法检测其中hc-HK蛋白含量,用酶联免疫吸附法检测其中Aβ42和KLK-6蛋白的含量;并对Aβ42与KLK-6进行相关性分析。结果 AD患者外周血中hc-HK含量较VD组或对照组均显著增加(均P<0.01)。AD组患者血液中的KLK-6水平为(4.80±0.78)ng/mL,VD组KLK-6为(3.72±0.87)ng/mL,AD组较VD组明显增加(t=3.57,P<0.01)。AD组患者血浆中Aβ42蛋白浓度为(0.261±0.024)μg/L,与VD组或对照组比较均明显增加(均P<0.01)。通过相关分析发现,在AD组患者血液中KLK-6与Aβ42的增加呈正相关(r=0.65,P<0.01)。结论AD患者外周血液中hc-HK和KLK-6蛋白比VD患者及非痴呆对照有明显增加,提示AD发病中有血凝接触系统的激活;激肽释放酶-激肽系统的异常激活有可能参与了AD的发病过程。
